The global burden of Alzheimer disease (AD) is growing rapidly with the aging of the world's population: There were an estimated 35.6 million people living with dementia worldwide in 2010, with numbers predicted to nearly double every 20 years. 1 In the United States, the number of adults age 65 and older with AD is expected to reach 7.1 million by 2025-a nearly 35% increase from the 5.3 million affected individuals in 2017. 2 Patients with AD are affected not only by the memory loss and cognitive decline that are hallmarks of the disease but also by a wide range of neuropsychiatric symptoms (NPS) that include agitation, mood disorders, psychosis, and sleep disturbances. 3 NPS are experienced by nearly all patients with dementia at some point during the course of their disease [4] [5] [6] and exacerbate the already substantial social and economic burden exacted by AD, contributing to increased morbidity, mortality, and institutionalization among patients with AD 7, 8 and to psychological distress and other health problems among their caregivers. 2, [8] [9] [10] In fact, the effect of NPS on patient and caregiver quality of life is consistently found to be even more detrimental than that of functional or cognitive impairment, 7, 9, [11] [12] [13] leading to widespread acknowledgement of NPS as a public health priority in neurodegenerative disease. 3 Agitation, characterized by excessive psychomotor activity, physical or verbal aggression, disruptive irritability, and disinhibition, 3 is one of the most common NPS among patients with dementia, with prevalence estimates ranging from 40% to 60%. 4, [14] [15] [16] [17] In addition to being one of the most distressing NPS for caregivers, 10, 14 agitation has been associated with faster progression to severe dementia, functional decline, increased risk of institutionalization, and earlier death. [18] [19] [20] [21] [22] [23] [24] [25] Management of agitation is thus a critical factor in the care of patients with AD, but no drugs at present have been approved in the United States for treating agitation in the population with dementia. Clinicians therefore turn to off-label prescription of antipsychotics, sedatives, and other psychoactive drugs when nonpharmacological approaches are insufficient and/or patients' symptoms are severe.
Unfortunately, these treatments are limited by concerns regarding efficacy, safety, and tolerability. 3, 26 Although recent progress in elucidating the mechanisms that may underlie NPS has spurred optimism regarding potential pharmacological treatments for AD, clinical research in the field has historically been hampered by heterogeneity in entry criteria and outcome measures among studies. 3 To help advance research into agitation among patients with dementia, the International Psychogeriatric Association (IPA) in 2015 released a provisional consensus definition that broadly defined agitation as excessive motor activity or verbal/physical aggression that (1) occurs in a patient with cognitive impairment or dementia syndrome, (2) is accompanied by evidence of emotional distress, (3) results in disability beyond that caused by cognitive impairment, and (4) is not solely attributable to another condition. 27 Development and utilization of this definition are expected to facilitate high-quality clinical and epidemiological investigations addressing agitation among patients with AD and other cognitive disorders by helping to define study populations and standardize baseline assessment. 27 Given the profound impact of NPS on quality of life and the evidence that the presence of these symptoms may affect the course of AD, the relationship between agitation and AD disease stage is an important research target that could help inform both study design and treatment decisions. 28 However, little has been published on the overall prevalence of agitation among community-based patients, and existing data originate from clinical studies that used specialized rating scales and/or psychiatric evaluations that may not be widely performed in real-world practice. [29] [30] [31] We therefore conducted an analysis to estimate the prevalence of agitation symptoms in a sample of US patients with AD/dementia and the prevalence of agitation by AD/dementia disease severity. This study was performed using terms consistent with the IPA provisional definition of agitation in conjunction with data from electronic health records (EHR), which leverages information from patients' medical records to provide a wide range of clinical data on a population level.
| MATERIALS AND METHODS

| Data source
This was a retrospective observational analysis using data from the • The prevalence of agitation was highest among patients with moderate-to-severe and severe AD/dementia.
• While a majority of published studies have shown a high prevalence of agitation in the long-term care setting, this study indicates that agitation is also common among community-dwelling patients.
administrative data for clinical and inpatient stays, and coded diagno- In addition to the data described above, the key EHR data for this study comprised abstracted provider notes records, which were extracted from electronic notes via a natural language processing (NLP) system developed and maintained by Optum Analytics (OA;
Boston, Massachusetts For patients who had an explicit AD/dementia severity level (ie, at least one notes record for probable AD/dementia with an explicit severity level and/or at least one notes record with a valid MMSE FIGURE 1 Sample selection and attrition flow diagram. AD, Alzheimer disease; EHR, electronic health records; MMSE, Mini-Mental Status Examination *"Probable" for this analysis meant it was inferred that the patient had the condition or symptom of interest based on clinician review of the terms in the abstracted provider notes records. Notes records that indicated patients did not have dementia, did not indicate direct observation of the patient and his or her symptoms, contained uninterpretable or invalid MMSE scores, or were not from direct physician encounters were not categorized as "probable." Main terms for AD/dementia were Alzheimer disease, Alzheimer dementia, dementia, senile dementia, presenile dementia, multiple infarction dementia, vascular dementia, subcortical vascular dementia, and arteriosclerotic dementia.
score indicating mild, moderate, or severe AD/dementia), the index date was the date of the first record with an explicit severity level.
For patients with at least one notes record indicating probable AD/dementia but no records indicating explicit severity, the index date was the date of the first record indicating probable AD/dementia. Finally, for patients who had no notes records indicating probable AD/dementia, the index date was the date of the first AD/dementia diagnosis record. To be included in the final study sample, patients were required to have at least two EHR records each during the 12 months before and after the index date (preindex and postindex periods, respectively), at least one EHR record each before the beginning of the preindex period and after the end of the postindex period, and no EHR diagnosis records for non-Alzheimer dementia during the preindex or postindex periods (Table A2 ).
| Study measures
Preindex patient characteristics included age, sex, and Charlson comorbidity score, 32 which was calculated using EHR diagnosis (Table 1) and abstracted notes records with agitation-related main terms were reviewed to identify those indicating probable agitation symptoms.
The final list included 126 main terms from notes records, categorized into 19 symptoms (Table A3 ). In all, 1 396 455 different term combinations representing a total of 44 539 115 abstracted notes records were manually reviewed to identify probable agitation. Patients with agitation symptoms were identified with a binary indicator.
| AD/dementia severity categorization
AD/dementia severity category assignments were based on MMSE scores and physician notes ( Table 2) . Patients who had notes records containing valid quantitative MMSE scores or explicit terms for only one level of AD/dementia severity during the postindex period were categorized accordingly as "mild," "mild-to-moderate," "moderate,"
"moderate-to-severe," or "severe." For patients whose notes records contained multiple severity levels, a severity category was determined by examining the chronological distribution of severity levels, as described in Table 2 . Patients whose notes records contained no explicit AD/dementia severity information, contained only qualitative AD/dementia severity or MMSE scores, or suggested a clinically unlikely progression (eg, severe to mild) were categorized as "unknown."
| Statistical analysis
Demographic characteristics were compared between patients with and without agitation using two-sample t tests for continuous variables (with Satterthwaite approximation for unequal variances)
and Pearson chi-squared tests for categorical variables. Outcomes were analyzed descriptively. SAS 9.4 (SAS Institute, Cary, North Carolina) was used for all statistical analyses.
3 | RESULTS
| Study sample and prevalence of agitation
The full study sample ( (Figure 2 ).
Of the 320 886 eligible patients, 78 827 (24.6%) could be assigned to explicit AD/dementia severity categories. The prevalence of agitation in the staged subgroup was 61.3% (Table 4 ). The distribution of staged patients by AD/dementia severity level was as follows: 
| DISCUSSION
Studies evaluating symptoms of agitation among patients with dementia are frequently conducted in a long-term care setting. To our knowledge, the present study is the first to use electronic health record data to estimate agitation prevalence among patients with dementia living in the community. In this large-scale analysis, the prevalence of agitation during the 2-year observation period was substantial: 44.6% in the full study sample and 61.3% in a subset of patients with staged AD/dementia severity. This constitutes not only a considerable strain on patient and caregiver health but also a considerable economic burden, as agitation has been shown to engender high additional costs compared with cognitive impairment alone. 22, 33 In a recent UK study, the presence of agitation was associated with significantly increased health care costs among home-dwelling patients with AD, accounting for mean excess costs of £2 billion per year. 33 Our agitation prevalence estimates fall within the 18% to 87% range described by a recent systematic review of previous studies on NPS in dementia. 28 Point prevalence rates for agitation/wandering and mechanical/motor abnormalities have previously been reported in the range of 18% to 57% 5, 30 and 10% to 61%, 5,34 respectively.
5,6,10,35
The variation in reported rates may be attributable to methodological differences due to earlier studies defining NPS using the Neuropsychiatric Inventory (NPI), an assessment tool commonly used in clinical studies to screen for behavioral symptoms among patients with dementia. 36 First, while we identified agitation on the basis of EHR notes from direct physician encounters and available diagnosis codes, the NPI is conducted via an interview with the patient's primary caregiver, whose assessment of agitation may differ from that of a physician. Second, the degree to which items assessed in the NPI overlap with the IPA provisional definition of agitation is not clear. Notably, relatively few patients had a diagnosis code for behavioral disturbance in the EHR diagnosis table (1.4% preindex, 4.9% postindex) despite nearly 45% of the study population having notes records that referred to agitation during the observation period.
Because the EHR diagnosis table is not used for billing, information in the table may not reflect claims submitted for payment. The lack of behavioral disturbance diagnosis codes observed in EHR may suggest that this symptom is underestimated in administrative claims data, which bolsters the argument for assessing symptoms using data from EHR in addition to claims. Not all conditions discussed between a physician and patient during an office visit will be coded on a claim, 37 and many conditions-including various agitation-related symptoms-do not have a specific ICD code, reducing the likelihood that they will be captured. Claims data therefore may not provide a from a baseline level of 39% and then declined to 46% in year 5.
A similar pattern was observed by Lovheim et al, 41 who found that agitation symptoms such as wandering, aggression, restlessness, and verbally disruptive behavior were most prevalent among institutionalized patients in the middle stages of cognitive impairment.
One possible explanation for these observations is that the diminished verbal ability and motor function associated with late-stage dementia may mask the manifestation of certain NPS among patients with advanced disease.
41
Our assessment of agitation prevalence by AD/dementia severity was limited by the preponderance of unknown staging:
Only 24.6% (78 827 of 320 886) of patients in the study sample could be assigned to explicit AD/dementia severity categories. This limitation is a source of potential confounding, as the observation that agitation was present among only 45% of the total study sample vs 61% of staged patients suggests that patients with notes records indicating AD/dementia severity may have been more likely to have documented agitation symptoms and that agitation may have been underreported in the total population. The insufficiency of notes records from our EHR database to evaluate AD/dementia severity for most patients is likely attributable to multiple reasons, including a lack of AD/dementia severity information in EHR notes, the inability of NLP to effectively capture the extent of variation in charting practices among physicians, and disparities in the volume and content of electronic notes available from provider organizations represented in the EHR database. In addition, only notes records from direct encounters between physicians and patients were examined in this study. As NLP often generates more than one notes record from a single full-text note and patients have notes records over time, there are multiple opportunities to identify a patient with a probable condition; nevertheless, some patients' severity status may have been missed because notes records from sources such as phone calls, emails, encounters with nonphysician health care providers, and interactions with caretakers
were not interpreted.
Although the utilization of an EHR database to access diverse clinical information at large sample sizes was a strength of this study, the EHR data also have certain limitations that should be considered. Not every pertinent detail of a patient's health status will be reflected in EHR, and data for patients who receive some of their care from provider delivery organizations whose data are not included in the EHR database are incomplete. Furthermore, the EHR database contains data primarily from community-dwelling patients; therefore, mild or moderate AD/dementia is likely overrepresented and severe dementia underrepresented in the study sample, and the study findings cannot be generalized to residents of long-term care facilities. Given the potential incompleteness of EHR data, the lack of long-term care residents in the study population, and the fact that only EHR from direct physician encounters were evaluated, our analysis may underestimate the true prevalence of agitation in the total population of patients with AD/dementia. Finally, it is possible that patients with mild dementia may have been less likely to have a dementia severity categorization due to less frequent use of health care services, which may present fewer opportunities for severity evidence to show up in the EHR database. This scenario could have resulted in those with mild dementia being overrepresented among unstaged patients and underrepresented among staged patients, contributing to the lower prevalence of agitation observed for unstaged vs staged patients in the present study. However, it should be noted that the prevalence of agitation among staged patients in this analysis was comparable with that found in clinical studies in which dementia severity was determined via cognitive evaluation rather than from administrative claims or EHR data, 29, 31 suggesting that our results were not substantially affected by this potential bias. data, and Caitlin Elliott, MS (Optum) for assistance with performing and verifying the data analysis. www.optum.com/resources/library/benefit-using-both-claims-dataelectronic-medical-record-data-health-care-analysis.html. 
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